These findings not only deepen our understanding of the regulatory mechanisms underlying tumor immune escape but also provide solid theoretical evidence for the translational application of the combination of NMT1 inhibition and PD-1 blockade in cancer therapy. Here, PDCD1 is linked to neoplasm.